Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-12-11

Clinical Trial Update: Sex/Gender Differences in Risk and Resilience to PTSD; Implication of Oxytocin [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing sex/gender differences in risk and resilience to PTSD and the role of oxytocin; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Oxytocin (Oxytocin)

Snippet

Sponsor: Megan Moran-Santa Maria | Conditions: PTSD | Phase 2 | Status: COMPLETED | Results posted: 2018-12-11